ArticleInfection and drug resistance2025
Shu-Feng-Jie-Biao Formula Ameliorates Influenza A Virus-Induced Acute Lung Injury by Inhibiting NF-κB and ERK MAPK Signaling Pathways.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A visualization analysis of Traditional Chinese Medicine for influenza prevention and treatment: advances, hotspots, and future trends.Frontiers in medicine · 2026Pooled it
- Network pharmacology-guided optimization of Semen Sojae Praeparatum fermentation for enhanced anti-influenza efficacy.Scientific reports · 2026Article
- Post-translational modification networks as master regulators of influenza virus replication, host adaptation, and immune evasion.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Shu-Feng-Jie-Biao formula (SFJBF) has been used to treat acute respiratory infections for a dozen years. This study aimed to explore its mechanisms and effects for the treatment of influenza. Methods: Network pharmacology was used to explore the underlying mechanism of SFJBF against influenza. The protective effects of SFJBF in vivo were evaluated by lung indexes, body weight loss and pathological changes in lungs. The anti-inflammatory effects in vivo were evaluated by flow cytometry and ELISA. RAW264.7 cells stimulated with imiquimod (R837) were used to determine the anti-inflammatory effects of SFJBF. Neutrophils isolated from bone marrow were activated by phorbol 12-myristate 13-acetate (PMA) to validate the effects of the active components of SFJBF. Results: SFJBF protected body weight loss, decreased lung indexes, reduced total protein content in lungs and mitigated pathological changes in mice. SFJBF inhibited the expression of chemokines ( Conclusion: SFJBF ameliorated virus-induced lung injury by suppressing overactivated immune responses via NF-κB and ERK MAPK signaling pathways, thereby protecting mice from influenza virus infection. SFJBF could be considered a potent therapeutic agent for treating influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.